Phase 3Not yet recruitingAge-related condition
USTiGA (MED3-202401)
A Randomized, Double-Blind, Phase II Investigator Initiated Trial of Upadacitinib and Short Glucocorticoid Tapering in Giant Cell Arteritis
- Sponsor
- Rheinische Friedrich-Wilhelms-Universitaet Bonn (Industry)
- Enrolment
- 70 planned
- Conditions
- Giant Cell Arteritis
- Interventions
- Prednisolon 20 mg JENAPHARM; UPADACITINIB; Prednisolon 10 mg JENAPHARM; P-Tabletten weiß 8 mm Lichtenstein; Prednisolon 5 mg JENAPHARM; Prednisolon 1 mg JENAPHARM
- Ages
- adults, older adults
- Registry
- CTIS2025-523199-22-00
Full record on the EU Clinical Trials Information System
From the registry
Main objective: To assess the efficacy of upadacitinib and shortened prednisolone therapy scheme in achieving sustained remission of GCA
Primary outcomes
- Percentage of participants achieving sustained remission from week 12 through week 52
History
Registered